Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD)

Nephrology Dialysis Transplantation

Volumn 27, Issue SUPPL.4, 2012, Pages

  Verdalles, Ursula ^a   De Vinuesa, Soledad García ^a   Goicoechea, Marian ^a   Quiroga, Borja ^a   Reque, Javier ^a   Panizo, Nayara ^a   Arroyo, David ^a   Luño, José ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

bioimpendance; diuretics; resistant hypertension; volume expansion

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIURETIC AGENT; DOXAZOSIN; FUROSEMIDE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ALBUMINURIA; ARTICLE; BIOIMPEDANCE SPECTROSCOPY; BLOOD PRESSURE REGULATION; BODY WATER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURESIS; DIURETIC THERAPY; DRUG SUBSTITUTION; EXTRACELLULAR SPACE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEINURIA; RESISTANT HYPERTENSION; SPECTROSCOPY; SYSTOLIC BLOOD PRESSURE;

AGED; DIELECTRIC SPECTROSCOPY; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; PILOT PROJECTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84871823747     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs420     Document Type: Article

References (12)

1. Chobanian AV, Bakris GL, Black HR et al. National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Peralta CA, Hicks LS, Chertow GM et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005; 45: 1119-1124.
3. Moissi UM, Wabel P, Chamney PWet al. Body fluid volume determination via body composition spectroscopy in health and disease. Physiol Meas 2006; 27: 921-933.
4. Wizemann V, Wabel P, Chamney P et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 1574-1579.
5. Crepaldi C, Soni S, Chionh CY et al. Application of body composition monitoring to peritoneal dialysis patients. Contrib Nephrol 2009; 163: 1-6.
6. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
7. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Hypertension 2007; 49: 839-845.
8. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009; 150: 776-783.
9. Martell N, Rodriguez-Cerrillo M, Grobbee DE et al. High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension. Blood Press 2003; 12: 149-154.
10. Cushman WC, Ford CE, Cutler JA et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.
11. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006; 69: 967-973.
12. Passauer J, Petrov H, Schleser A et al. Evaluation of clinical dry weight assessment in haemodialysis patients using bioimpedance spectroscopy: a cross-sectional study. Nephrol Dial Transplant 2010; 25: 545-551.